OncoCyte Corporation (OCX)

NASDAQ: OCX · Real-Time Price · USD
2.870
+0.030 (1.06%)
At close: May 9, 2025, 4:00 PM
2.860
-0.010 (-0.35%)
After-hours: May 9, 2025, 6:06 PM EDT
1.06%
Market Cap 82.08M
Revenue (ttm) 1.88M
Net Income (ttm) -60.93M
Shares Out 28.60M
EPS (ttm) -4.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,471
Open 2.870
Previous Close 2.840
Day's Range 2.811 - 2.960
52-Week Range 1.922 - 4.750
Beta 0.96
Analysts Strong Buy
Price Target 4.42 (+54.01%)
Earnings Date May 19, 2025

About OCX

OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monito... [Read more]

Sector Healthcare
Founded 2009
Employees 49
Stock Exchange NASDAQ
Ticker Symbol OCX
Full Company Profile

Financial Performance

In 2024, OncoCyte's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for OCX stock is "Strong Buy." The 12-month stock price forecast is $4.42, which is an increase of 54.01% from the latest price.

Price Target
$4.42
(54.01% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after...

2 days ago - GlobeNewsWire

Oncocyte Provides Positive Update on Clinical Trial Progress

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiati...

9 days ago - GlobeNewsWire

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings adv...

10 days ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andr...

6 weeks ago - Seeking Alpha

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results ...

7 weeks ago - GlobeNewsWire

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial...

3 months ago - GlobeNewsWire

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business develo...

4 months ago - GlobeNewsWire

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (D...

4 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke ...

6 months ago - Seeking Alpha

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results...

6 months ago - GlobeNewsWire

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Ev...

7 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

9 months ago - Seeking Alpha

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics compa...

11 months ago - GlobeNewsWire

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney ...

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Con...

1 year ago - Seeking Alpha

Oncocyte Reports First Quarter 2024 Financial Results

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2023 Results Conference Call April 12, 2024 8:00 AM ET Company Participants Jeff Ramson - PCG Advisory Josh Riggs - President, CEO Conference Call Participants Mi...

1 year ago - Seeking Alpha

Oncocyte Reports Full Year 2023 Financial Results

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

1 year ago - GlobeNewsWire

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2...

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Pa...

1 year ago - Seeking Alpha

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call P...

1 year ago - Seeking Alpha

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal

1 year ago - GlobeNewsWire

Oncocyte Announces 1-For-20 Reverse Stock Split

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 revers...

1 year ago - GlobeNewsWire

Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics comp...

2 years ago - GlobeNewsWire

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevar...

2 years ago - Newsfile Corp